Vedolizumab
Based on 3 publication(s) in Google Scholar
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.90%
- No. CAS: 943609-66-3
- Peso molecular:146.868 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-108831
NatalizumabAnti-α4 Integrin Monoclonal Antibody -
HY-P9984
Etrolizumabβ7 Integrin Inhibitor -
HY-P9970
InfliximabTNF-α Inhibitor -
HY-P9909
Ustekinumab -
HY-P99184
AbrilumabAnti-Human α4β7 -
HY-P9908
AdalimumabTNF-α Inhibitor -
HY-108831A
Natalizumab (Anti-CD49d)Anti-α4 Integrin Monoclonal Antibody -
HY-P9931
GuselkumabIL-23 Neutralizing Antibody -
HY-P99248
RisankizumabIL-23 IgG Monoclonal Antibody -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-P99737
MirikizumabIL-23 Antibody -
HY-P9911A
Vedolizumab (anti-α4β7-integrin)
Publications Citing Use of MedChemExpress (MCE) Vedolizumab
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
ELISA
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Integrin a4b7
In Vitro
Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC50=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC50=0.02-0.06 μg/mL) and fibronectin (IC50=0.02 μg/mL), but not vascular cell adhesion molecule 1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Jurkat cells with Vedolizumab (HY-P9911, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized Human Integrin alpha 4 beta 7 Protein (His Tag) can bind Vedolizumab. The EC50 for this effect is 119.52 ng/mL.
Chemical Information
-
No. CAS 943609-66-3
-
Appearance Liquid
-
Peso molecular 146.868 kDa
-
Color Colorless to light yellow
-
SMILES
[Vedolizumab]
-
Synonyms
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Microenvironment to Boost Probiotic Therapy in Inflammatory Bowel Disease. [Abstract]2025 Jan;37(4):e2412429. PMID: 39641224
Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]
Vedolizumab (5 mg/kg; i.v.; once every two days) decreased MPO levels in DSS-treated mice.
Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]
Vedolizumab (5 mg/kg; i.v.; once every two days for 10 d) effectively repaired pathological damage in the colonic tissues of IBD mice.
Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]
Vedolizumab (5 mg/kg; i.v.; once every two days for 10 d) significantly decreased colonic TNF-α, IL-6, and IL-1β levels in IBD mice.
-
Brain Behav Immun
Pro-inflammatory macrophages contribute to developing comorbid anxiety-like behaviors through gastrointestinal vagal afferent signaling in experimental colitis mice. [Abstract]2025 May 8:128:620-633. PMID: 40348137
Vedolizumab purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]
Vedolizumab (30-50 mg/kg; i.p.; 4 d) significantly reduced the disease activity index of DSS-induced colitis mice.
Vedolizumab purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]
Vedolizumab (30-50 mg/kg; i.p.; 4 d) significantly reduced histological damage of colon tissues of DSS-induced colitis mice.
-
Anal Chim Acta
Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]2021 Apr 15:1154:338306. PMID: 33736796
Protocolo
Kinase Assay[1]
Vedolizumab inhibition of high-affinity binding of MAdCAM-1 to human peripheral blood memory CD4+ T lymphocytes is tested. Peripheral blood (90 μL) is incubated with a saturating concentration (3 μg/mL) of MAdCAM-1-murine-Fc fusion protein and 4 mM MnCl2 in a final volume of 100 μL for 1 h at room temperature, in the presence or absence of vedolizumab. After washing with assay buffer, the cells are stained with fluorescentlabeled anti-mouse IgG for 15 min at room temperature. After washing again, cells are incubated with mouse serum for 10 min at room temperature, followed by staining with anti-CD4 and anti-CD45RO antibodies for 15 min at room temperature. After washing, red blood cells are lysed with BD FACS lysing solution and analyzed by flow cytometry in a FACSCalibur with CellQuest Pro software[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (263 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [Content Brief]
[2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vedolizumab Related Classifications
HY-P9911 Related Classifications
Powered by Bioz